Clinical trials: Major Depressive Disorder, Recurrent, Unspecified
Schizophrenia, Schizotypal Disorder
Feasibility of a Novel Process-based Treatment for Patients With Psychosis
The purpose of this single-arm feasibility study is to develop and pilot test a novel process-based and modular group therapy approach for patients with acute psychotic symptoms in an inpatient setting.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Brief Psychotic Disorder
- Trial name
- PROBAS (NCT04874974)
- Testing
- Metacognitive and Defusion Training
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Major Depressive Disorder, Recurrent, Unspecified, Major Depressive Disorder, Single Episode, Unspecified
Prospective Multicenter Trial to Explore the Tolerability and Safety of the H-Coil Deep TMS in Combination With Serotonin Selective Reuptake Inhibitor(SSRI)
The purpose of the study is to explore the Tolerability and Safety of the H-Coil deep Transcranial Magnetic Stimulation (TMS) in combination with Serotonin Selective Reuptake Inhibitor (SSRI) for Subjects with Major Depression…
- Trial name
- NCT01361815
- Testing
- H-Coil Deep TMS in combination with SSRIs
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 75 people
- Sponsor
- Brainsway
Major Depressive Disorder, Recurrent, Unspecified
Deep Brain Stimulation of Nucleus Accumbens for Chronic and Resistant Major Depressive Disorder
Depression is a common, recurrent and disabling disorder. Among patients with a chronic course of the disease, 20 to 30% are resistant to antidepressant medications.
- Trial name
- PRESTHYM (NCT01569711)
- Testing
- Deep brain stimulation of nucleus accumbens
- Where
- 10 sites in France
- Volunteers
- 6 people
- Sponsor
- Rennes University Hospital
Major Depressive Disorder, Recurrent, Unspecified
Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005
Objectives To evaluate the safety and tolerability of escalating multiple oral doses of LY03005 in healthy subjects. To characterize the pharmacokinetics of escalating multiple oral doses of LY03005.
- Trial name
- NCT02271412
- Testing
- LY03005
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Major Depressive Disorder, Major Depressive Disorder, Recurrent, Unspecified
Escitalopram, Placebo and tDCS in Depression: a Non-inferiority Trial
Major depressive disorder (MDD) is a common psychiatric condition, mostly treated with antidepressant drugs, which are limited for issues such as refractoriness and adverse effects.
- Conditions
- Major Depressive Disorder, Major Depressive Disorder, Recurrent, Unspecified, Major Depressive Disorder, Single Episode, Unspecified
- Trial name
- ELECT-TDCS (NCT01894815)
- Testing
- Escitalopram oxalate, transcranial direct current stimulation
- Where
- 2 sites in Brazil
- Volunteers
- 245 people
- Sponsor
- University of Sao Paulo